Clinical trial demonstrates divergent immune and hallmark pathways in metastatic castration-resistant prostate cancer, suggesting potential biomarkers for treatment response.
Supplementary Figure S8. Heatmap showing immune-related Level 1 Reactome and selected Cancer Hallmark pathways in bulk RNA sequencing of baseline metastatic lymph node biopsies from patients allocated to the Satisfactory (n=27) and Unsatisfactory (n=13) groups.
No takes yet. Share an insight, caveat, or question.
Aparicio et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: